Table 4. Risk for second lung, breast, or colorectal cancers stratified, respectively, on the presence of first-degree relatives with cancer overall or first-degree relative with cancer at risk.

			Presence of first-degree relatives with cancer overall
			Negative			Positive
Age at treatment	Second cancer, site	Years, after HL	O	SIR (95% CI)	AER	O	SIR (95% CI)	AER
All ages	Breast	⩾1	40	1.53 (1.10–2.09)	3.6	41	3.96 (2.83–5.36)	15.5
		1–9	8	0.65 (0.28–1.28)	—	7	2.31 (0.92–4.76)	4.3
		10–19	20	2.37 (1.45–3.66)	9.7	15	3.87 (2.16–6.38)	16.5
		⩾20	12	2.23 (1.15–3.90)	13.0	19	5.52 (3.32–8.62)	40.8
	Lung	⩾1	59	3.20 (2.44–4.13)	10.6	23	4.57 (2.89–6.86)	9.1
		1–9	25	2.69 (1.74–3.97)	7.4	6	3.55 (1.29–7.73)	4.7
		10–19	18	3.16 (1.87–4.99)	10.3	6	3.55 (1.29–7.73)	6.4
		⩾20	16	4.6 (2.64–7.51)	24.6	11	6.71 (3.34–12.00)	24.4
	Colorectal	⩾1	64	2.13 (1.63–2.71)	8.9	18	2.54 (1.50–4.01)	5.5
		1–9	31	2.05 (1.39–2.91)	7.5	6	2.43 (0.88–5.29)	3.8
		10–19	25	2.71 (1.75–4.01)	13.2	3	1.24 (0.25–3.64)	0.9
		⩾20	8	1.41 (0.60–2.78)	4.6	9	4.13 (1.88–7.84)	17.9

AER=absolute excess risk; CI=confidence interval; HL=Hodgkin's lymphoma; SIR=standardised incidence ratio.

Time after treatment divided into 1–9, 10–19, and 20 or over 20 years after treatment for HL. Male and female subjects combined. Treated for HL at all ages.